Two new screenings technics for the early detection of pancreatic neuroendocrine tumors in Multipele Endocrine Neoplasia type 1 (MEN1) and Von Hippel-Lindau disease (VHL).
Completed
- Conditions
- pancreatic neuroendocrine tumors in patients with MEN1 en VHL.
- Registration Number
- NL-OMON23812
- Lead Sponsor
- dr. T.P. Links
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
The study populations covers two different groups:
1. Group A: MEN1 or VHL patients with signs of a pancreatic tumor (biochemically and/or on conventional imaging) will undergo regular follow-up visits to control tumor localization. These patients are eligible for inclusion providing that the time period between the available conventional imaging data and the investigational imaging procedures does not exceed 4 months;
Exclusion Criteria
1. Patients with any signs of neurological or psychiatric disorders that will preclude him/her from expressing her/his own free will;
2. Pregnancy;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Group A:<br /> <br>The number of new (unknown) pancreatic NET lesions in MEN1 or VHL patients with proven pancreatic involvement (anatomical, with or without biochemical neuroendocrine activity) and in MEN1 or VHL patients with proven neuroendocrine activity (biochemical, without anatomical localization) detected by EUS ± FNA and 11C-HTP PET. <br><br /><br /><br>Group B:<br /><br>The number of new (unknown) pancreatic NET lesions in patiens with MEN1 or VHL during routine follow-up detected by EUS ± FNA and 11C-HTP PET. <br><br>
- Secondary Outcome Measures
Name Time Method